Notes to the Balance Sheet - Summary of DFB, Initial Measurement Loss (Details) - DFB, initial measurement [Member] - EUR (€) € in Thousands	12 Months Ended
Dec. 31, 2022	Dec. 31, 2021
Financial Liabilities Royalty Pharma [Line Items]
Development Funding Bond, measurement loss	€ 52,862	€ 0
Market Inequity	56,738
Amortization from Effective Interest Method	(1,173)
Gains (losses) on exchange differences on translation of foreign operations, net of tax	€ (2,703)

The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 91
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration